Effect of the menstrual cycle and hormonal contraceptives on human papillomavirus detection in young, unscreened women

Obstetrics and Gynecology

Volumn 116, Issue 1, 2010, Pages 67-75

  Schmeink, Channa E ^a   Massuger, Leon F ^b   Lenselink, Charlotte H ^b   Quint, Wim G ^b   Melchers, Willem J ^b   Bekkers, Ruud L ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CANCER PREVENTION; CANCER SCREENING; DRUG USE; FEMALE; HUMAN; INCIDENCE; INFECTION RISK; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; UTERINE CERVIX CANCER; VIRUS DETECTION; WART VIRUS;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MENSTRUAL CYCLE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE;

EID: 77954059326     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181e238f0     Document Type: Article

References (38)

1. Castellsague X, Bosch FX, Munoz N. Environmental co-factors in HPV carcinogenesis. Virus Res 2002;89:191-199
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kum-mer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189: 12-19
3. Bosch FX, de Sanjosé S. The epidemiology of human papillo-mavirus infection and cervical cancer. Dis Markers 2007;23: 213-227
4. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodhill A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007;370:1609-1621
5. Green J, Berrington de GA, Smith JS, Franceschi S, Appleby P, Plummer M, et al. Human papillomavirus infection and use of oral contraceptives. Br J Cancer 2003;88:1713-1720 (Pubitemid 36760415)
6. Schneider A, Kirchhoff T, Meinhardt G, Gissmann L. Repeated evaluation of human papillomavirus 16 status in cervical swabs of young women with a history of normal Papanicolaou smears. Obstet Gynecol 1992;79:683-688
7. Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lyt-wyn A, Chong S, et al. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 2003;168: 421-425
8. van Ham MA, Melchers WJ, Hanselaar AG, Bekkers RL, Boonstra H, Massuger LF. Fluctuations in prevalence of cervical human papillomavirus in women frequently sampled during a single menstrual cycle. Br J Cancer 2002;87:373-376
9. Sherman ME, Carreon JD, Schiffman M. Performance of cytology and human papillomavirus testing in relation to the menstrual cycle. Br J Cancer 2006;94:1690-1696
10. Fairley CK, Robinson PM, Chen S, Tabrizi SN, Garland SM. The detection of HPV DNA, the size of tampon specimens and the menstrual cycle. Genitourin Med 1994;70:171-174
11. Harper DM, Longacre MR, Noll WW, Belloni DR, Cole BF. Factors affecting the detection rate of human papillomavirus. Ann Fam Med 2003;1:221-227
12. Wheeler CM, Greer CE, Becker TM, Hunt WC, Anderson SM, Manos MM. Short-term fluctuations in the detection of cervical human papillomavirus DNA. Obstet Gynecol 1996; 88:261-268
13. Franklin RD, Kutteh WH. Characterization of immunoglobu-lins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. J Reprod Immunol 1999;42:93-106.
14. Safaeian M, Falk RT, Rodriguez AC, Hildesheim A, Kemp T, Williams M, et al. Factors associated with fluctuations in IgA and IgG levels at the cervix during the menstrual cycle. J Infect Dis 2009;199:455-463
15. Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003;95:1128-1137
16. Lenselink CH, Melchers WJ, Quint WG, Hoebers AM, Hen-driks JC, Massuger LF, et al. Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS One 2008;3:e3743.
17. Ogilvie GS, Patrick DM, Schulzer M, Sellors JW, Petric M, Chambers K, et al. Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sex Transm Infect 2005;81:207-212
18. Harper DM, Noll WW, Belloni DR, Cole BF. Randomized clinical trial of PCR-determined human papillomavirus detection methods: self-sampling versus clinician-directed\biologic concordance and women's preferences. Am J Obstet Gynecol 2002;186:365-373
19. Melchers WJ, Bakkers JM, Wang J, de Wilde PC, Boonstra H, Quint WG, et al. Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad spectrum of human papillomavirus types. Clinical evaluation and follow-up. Am J Pathol 1999;155: 1473-1478
20. van Hamont D, van Ham MA, Bakkers JM, Massuger LF, Melchers WJ. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test. J Clin Microbiol 2006;44: 3122-3129
21. de Villiers EM. Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. Int J Cancer 2003;103:705-708
22. Deacon JM, Evans CD, Yule R, Desai M, Binns W, Taylor C, et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer 2000;83:1565-1572
23. Syrjanen K, Shabalova I, Petrovichev N, Kozachenko V, Zakharova T, Pajanidi J, et al. Oral contraceptives are not an independent risk factor for cervical intraepithelial neoplasia or high-risk human papillomavirus infections. Anticancer Res 2006;26:4729-4740
24. Vaccarella S, Herrero R, Dai M, Snijders PJ, Meijer CJ, Thomas JO, et al. Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomark-ers Prev 2006;15:2148-2153
25. Veress G, Csiky-Meszaros T, Czegledy J, Gergely L. Oral contraceptive use and human papillomavirus infection in women without abnormal cytological results. Med Microbiol Immunol 1992;181:181-189
26. Cotton SC, Sharp L, Seth R, Masson LF, Little J, Cruickshank ME, et al. Lifestyle and socio-demographic factors associated with high-risk HPV infection in UK women. Br J Cancer 2007;97:133-139
27. Rousseau MC, Franco EL, Villa LL, Sobrinho JP, Termini L, Prado JM, et al. A cumulative case-control study of risk factor profiles for oncogenic and nononcogenic cervical human papillomavirus infections. Cancer Epidemiol Biomarkers Prev 2000;9:469-476
28. Sasieni P. Cervical cancer prevention and hormonal contraception. Lancet 2007;370:1591-1592
29. Riley RR, Duensing S, Brake T, Munger K, Lambert PF, Arbeit JM. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogene-sis. Cancer Res 2003;63:4862-4871
30. Brake T, Lambert PF. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci USA 2005;102:2490-2495
31. Veress G, Csiky-Meszaros T, Konya J, Czegledy J, Gergely L. Follow-up of human papillomavirus (HPV) DNA and local anti-HPV antibodies in cytologically normal pregnant women. Med Microbiol Immunol 1996;185:139-144
32. Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359:1085-1092
33. van Hamont D, Bekkers RL, Massuger LF, Melchers WJ. Detection, management, and follow-up of pre-malignant cervical lesions and the role for human papillomavirus. Rev Med Virol 2008;18:117-132
34. Syrjänen K. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors. Eur J Gynaecol Oncol 2008;29:205-221
35. Bertram CC. Evidence for practice: oral contraception and risk of cervical cancer. J Am Acad Nurse Pract 2004;16:455-461
36. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-1371
37. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiol Biomarkers Prev 2009;18:1060-1069
38. Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361:1159-1167